Zobrazeno 1 - 9
of 9
pro vyhledávání: '"M. Alex Michaels"'
Autor:
Eric F Morand, M Alex Michaels
Publikováno v:
Lupus Science and Medicine, Vol 8, Iss 1 (2021)
Objective In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We evaluated the safety and tolerability of anifrolumab using da
Externí odkaz:
https://doaj.org/article/436e0225e5244ce0ab6ed7b1a8c36a4d
Autor:
Richard Furie, Lilia Pineda, Raj Tummala, Rubana N Kalyani, Gabriel Abreu, Eric F Morand, M Alex Michaels
Publikováno v:
Lupus Science and Medicine, Vol 8, Iss 1 (2021)
Lupus Science & Medicine
Lupus Science & Medicine
ObjectiveIn phase II and III trials, anifrolumab, a human monoclonal antibody that binds type I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We evaluated the safety and tolerability of anifrolumab using dat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::100dc27178f87f041d90d3823eeacf7a
https://lupus.bmj.com/content/8/1/e000464.full
https://lupus.bmj.com/content/8/1/e000464.full
Autor:
M. Alex Michaels, Jiří Vencovský, A. Godwood, D. Close, Michael E. Weinblatt, Pedro Miranda, Xiang Guo, Iain B. McInnes, M. Albulescu, Joel M. Kremer, Gerd R Burmester
Publikováno v:
Arthritis & Rheumatology (Hoboken, N.j.)
OBJECTIVE Mavrilimumab, a human monoclonal antibody, targets granulocyte-macrophage colony-stimulating factor receptor α. We undertook to determine the long-term safety and efficacy of mavrilimumab in rheumatoid arthritis patients in 2 phase IIb stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bddbd34afdcd03df966cf7a8ccaff29
https://eprints.gla.ac.uk/156349/7/156349.pdf
https://eprints.gla.ac.uk/156349/7/156349.pdf
Publikováno v:
The Journal of rheumatology. 43(8)
Objective.To compare serious infection risk for systemic lupus erythematosus (SLE) patients starting glucocorticoids (GC), antimalarials (AM), or their combination.Methods.We conducted a new-user, historical cohort study, Kaiser Permanente Northern C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ce591e642f6f275cdeb44593f8532b8
https://pubmed.ncbi.nlm.nih.gov/27370880
https://pubmed.ncbi.nlm.nih.gov/27370880
Publikováno v:
Biological Psychiatry. 61:706-712
Background The cardiovascular safety of mixed amphetamine salts extended release (MAS XR) was evaluated in 2968 children 6–12 years of age with attention-deficit/hyperactivity disorder (ADHD). Methods In this prospective, open-label, noncomparative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0dff901403fd7358fac5a137e891af3
https://doi.org/10.1016/j.biopsych.2006.05.002
https://doi.org/10.1016/j.biopsych.2006.05.002
Publikováno v:
Current Medical Research and Opinion. 22:427-440
To assess the safety, tolerability, and effectiveness of mixed amphetamine salts extended release (MAS XR) in school-age children with attention-deficit/hyperactivity disorder (ADHD) treated in a community practice setting.Children aged 6-12 years (N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d43ce1710e966b4554fc759a956752e
https://doi.org/10.1185/030079906x80639
https://doi.org/10.1185/030079906x80639
Publikováno v:
Journal of attention disorders. 12(4)
Background: Psychostimulant treatment may improve simulated driving performance in young adults with attention-deficit/hyperactivity disorder (ADHD). Method: This was a randomized, double-blind, placebo-controlled, crossover study of simulated drivin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fa0bf3f21b91f586b0c338ec441b677
https://pubmed.ncbi.nlm.nih.gov/18815438
https://pubmed.ncbi.nlm.nih.gov/18815438
Autor:
Christopher J. Kratochvil, Benedetto Vitiello, Henrietta Leonard, Ernest D. Prentice, Albert Derivan, Kimberly Hoagwood, Stephen P. Hinshaw, John H. Heiligenstein, M. Alex Michaels, Gregory N. Clarke, John S. March, Trina Osher, William R. Beardslee, Theodore A. Petti, Graham J. Emslie, Evelyn Green, Philip W. Lavori, Peter S. Jensen, James McNulty, Karen C. Wells, Andrew Mossholder
Objective The use of placebo in the pediatric age group has come under increasing scrutiny. At the 2002 Annual Meeting of the American Academy of Child and Adolescent Psychiatry, the Academy's Workgroup on Research conducted a research forum. The pur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82dc21ba38f77a1ba808066816469b69
http://hdl.handle.net/2318/1646512
http://hdl.handle.net/2318/1646512
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.